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Abstract
Background: Over the past few decades, parathyroid
hormone (PTH) immunoassays have progressed through
successive generations resulting in increased specificity and accuracy for detecting circulating PTH. With the
introduction of third-generation assays, in which the
biologically active PTH(1-84) is specifically targeted, the
PTH(7-84) and other fragments are not detected. The specific recognition of only PTH(1-84) whole molecule allows
for more reliable standardization and calibration than
with the existing assays.
Methods: Samples from patients on hemodialysis or with
primary hyperparathyroidism and apparently healthy subjects were examined in different collection matrices (EDTA
plasma, unspun EDTA plasma and SST) stored for 0, 24 or
72 h at room temperature to reflect the prevailing sample
collection methods, shipping and processing conditions of
centralized labs in the United States. Samples were analyzed by the LIAISON 1-84 PTH and N-TACT assays, and by
three additional commercially available intact PTH assays.
Results: Defined samples, prepared using two different
standards (WHO 95/646 international standard and the
synthetic Bachem PTH(1-84)), show little bias with the
LIAISON 1-84 PTH assay, but not with the other intact
PTH assays. Furthermore, PTH is stable for up to 72 h in
plasma, but less stable in serum beyond 24 h.
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Conclusions: The FDA-approved LIAISON 1-84 PTH assay
is accurate and reliably measures the biologically active
PTH molecule in plasma or serum stored at room temperature for up 72 and 24 h, respectively.
Keywords:
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immunoassay;
hormone; stability; standards; trueness.
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Introduction
Parathyroid hormone (PTH) is essential for regulation of
calcium and phosphate homeostasis [1]. Intraoperative
assessment of parathyroidectomy discloses a detectable
half-life of approximately 3 min [2]. Accurate measurement of serum PTH levels is critical for the diagnosis of
hyper- and hypoparathyroid disorders and for monitoring
patients with chronic kidney disease.
Although PTH(1-84) is the biologically active
hormone, PTH carboxyl fragments that lack the N-terminal amino acid sequence required for biological activity
(i.e. PTH(7-84) and others) are also present in the circulation as a result of glandular secretion or peripheral degradation of the hormone [3].
Over the past 2–3 decades PTH immunoassays have
progressed through a succession of generations resulting in increased specificity and trueness for detecting PTH. The commonly used intact PTH (iPTH) assays
(second generation) not only measure the biologically
active PTH(1-84) but also detect, to varying degrees, inactive fragments such as the PTH(7-84) fragments, and the
measurements are thus widely variable [4, 5]. With the
introduction of third-generation assays in which only the
biologically active PTH(1-84) whole peptide is specifically
targeted, greater specificity is realized enabling proper
standardization, greater trueness and consistent measurements. Unlike third-generation PTH assays, intact PTH
assays are not commutable due to their variable reactivity
to inactive PTH(7-84) fragments [6].
Against this historic composite, PTH stability studies
to date have been performed with various outcomes
This work is licensed under the Creative Commons Attribution-
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attributable to assay variability, temperature and matrix
parameters [7]. The need for a multifactorial study was
confirmed in a recent study by Schleck et al. [8] whose
study design was similar to ours. However, the present
study design is more expansive using more patient types,
more platforms and most importantly, longer storage
times that best represent the current routine flow within
the centralized U.S. laboratory system. Furthermore,
traceability to the World Health Organization (WHO)
International Standard was explored to determine trueness of the methods.

Materials and methods
The experimental design for the study is shown in Figure 1: hemodialysis, primary hyperparathyroid or apparently healthy subjects

Patient
type
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(n = 5 each) were enrolled from three different sites: Saint Louis
University, Henry Ford Hospital and LabCorp. For each patient, nine
tubes (three time points for each of three sample types) were collected: (1) K2 EDTA plastic lavender top vacutainers and centrifuged
within 30 min of draw (plasma), (2) K2 EDTA plastic lavender top
vacutainers stored uncentrifuged (unspun plasma) and (3) serum
separator gold top vacutainers centrifuged within 45–60 min to separate serum from the clot (SST). Tubes were stored at room temperature for 0, 24 or 72 h, followed by storage in 1 mL aliquots at −80 °C.
Unspun tubes were centrifuged after storage immediately prior to
aliquoting. Following collection, the frozen samples were shipped
to LabCorp for PTH measurement on five different analyzers whose
assay parameters are described in Table 1. The data were analyzed
by a multifactor analysis of variance fitted separately for each tube
type, with storage duration and patient type as factors. Analytical
variability, taken from the manufacturers’ reported precision studies, was comparable between assays with repeatability parameters
ranging from ~3 to 5 %CV or less, with the 1-84 PTH LIAISON assay
having imprecisions of 3.1%–4.9% and 4.0%–7.2% for repeatability
and reproducibility, respectively (Table 1) [9].

Apparently healthy (n = 5)
Primary hyperparathyroid (n = 5)
Hemodialysis (n = 5)

Tube
type

Plasma EDTA
Unspun plasma EDTA
Serum separator
Storage
at room
temp

0h
24 h
72 h

Analyzer

LIAISON 1-84 PTH
LIAISON N-TACT PTH
Method A intact PTH
Method B intact PTH
Method C intact PTH

Figure 1: Experimental design.
Patient types, matrices, storage times and analyzer platforms are outlined culminating in a total of 675 measurements.

Table 1: Description of parameters of the assays used.
LIAISON 1-84 PTH
Assay measuring range 4.0–1800 pg/mL
Calibration standard
Bachem synthetic 1-84
peptide traceable to
WHO 95/646
Epitope specificity
Capture
39–84 fragment
Detection
Serine 1
Detection chemistry
ABEIb
Precision (%CV)
Within-run
3.1%–4.9%
Total
4.0%–7.2%

LIAISON N-TACT II

Method Aa

Method Ba

Method Ca

3.0–1900 pg/mL
WHO 95/646 standard
traceable to WHO
95/646

2.5–1900 pg/mL
1.20–5000 pg/mL 3.0–2500 pg/mL
Purified human
Not reported
Not reported
1-84 PTH traceable to
WHO 79/500

39–84
1–34
ABEI

39–84
1–34
Acridinium ester

1–37
38–84
Ruthenium

44–84
1–34
Alkaline phosphatase

3.9%–6.1%
5.1%–8.9%

3.4%–5.2%
4.6%–7.8%

0.6%–2.8%
1.6%–3.4%

4.2%–5.7%
6.3%–8.8%

Data were taken from manufacturer’s kit instructions for use. bABEI, N-(4-aminobutyl)-N-ethyl-isoluminol.

a
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For trueness assessment, the WHO International Standard
PTH(1-84), human, recombinant NIBSC code: 95/646 (Hertfordshire, UK) [10, 11], or Bachem synthetic PTH(1-84) (PN H-1370,
Torrance, CA, USA) was spiked into charcoal-stripped, heat-inactivated human serum at concentrations ranging from 0 to 1000 pg/
mL. The samples were analyzed for PTH content by the different
methods. The distribution of inactive PTH fragment was assessed
in 1533 hemodialysis patients by measuring both PTH(1-84) with
the LIAISON method, and iPTH with Method A because of its high
cross-reactivity with inactive fragments [4]. The fragment content
was calculated as (iPTH-PTH(1-84))/iPTH and expressed as % of
total iPTH.
The study protocol was approved by the respective Institutional
Review Boards of the respective sites.

Results
One of the major criticisms of commercial PTH assays has
been that none of the intact PTH assays have been calibrated to the 95/646 WHO PTH1-84 standard [12]. This is
largely due to the detection of PTH fragments in the iPTH

assays. The data in Figure 2 show WHO standards prepared at concentrations ranging between 0 and 1000 pg/
mL and the corresponding measured values of PTH
derived from the different methods. The LIAISON 1-84 PTH
measures the WHO recombinant PTH(1-84) standard with
little bias as evidenced by its close alignment with the line
of identity, thereby corroborating the reliable standardization, calibration and commutability of this FDA-approved
assay. Closely aligned data were observed when trueness was assessed using the synthetic Bachem PTH(1-84)
standard (data not shown).
All samples in the stability study were normalized to the time = 0 h plasma sample for analysis. In
Figure 3, average deviations for all 15 patients from the
baseline plasma sample at each time point are plotted
for the five different platforms and three sample types.
Box-Cox methodology recommended that the analysis
be made on log-transformed values, which are shown
on the y-axes of these plots. Table 2 presents the same
data expressed as % change from the plasma sample
(T = 0 h). Little variability was observed for plasma and

Figure 2: WHO standards prepared at concentrations ranging between 0 and 1000 pg/mL in charcoal-stripped heat-inactivated human
serum were assessed with each assay and plotted against each standard.
(A) Alignment at PTH(1-84) concentrations between 0 and 100 pg/mL (range for apparently healthy and most primary hyperparathyroid).
(B) Alignment over the entire tested range (0–1000 pg/mL).
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0.4

1-84 PTH LIAISON
Ln (ratio to baseline)

0.2

0

Baseline
24 h

–0.2

72 h

–0.4

–0.6

Unspun plasma
Collection tube type

0.4

0.4

0.2

0.2
Intact PTH Method A
Ln (ratio to baseline)

N-TACT PTH LIAISON
Ln (ratio to baseline)

Plasma

0

–0.2

–0.4

0

–0.2

–0.4

–0.6

–0.6
Plasma

Unspun plasma
Collection tube type

SST

0.4

0.4

0.2

0.2
Intact PTH Method C
Ln (ratio to baseline)

Intact PTH Method B
Ln (ratio to baseline)

SST

0

–0.2

–0.4

Plasma

Unspun plasma
Collection tube type

SST

Plasma

Unspun plasma
Collection tube type

SST

0

–0.2

–0.4

–0.6

–0.6
Plasma

Unspun plasma
Collection tube type

SST

Figure 3: Deviation from reference sample.
The log-transformed values of the ratio of measurement to the reference value (plasma at T = 0 h) were plotted as an average with 95%
confidence interval for the 15 subjects in the study for each sample type and storage time. The corresponding values expressed in percent
change are shown in Table 2.

unspun plasma over the first 24-h storage period for the
PTH(1-84) and iPTH on the LIAISON analyzers and for
iPTH by Method B. Method A and Method C were more
variable but not significantly different from baseline for
plasma and unspun plasma. Most notable, however, is
that serum is significantly less stable than plasma when

samples are stored at room temperature for 72 h regardless of platform, even when separated from the clot by
centrifugation within 1 h. The stability of PTH in unspun
plasma for 72 h at room temperature was confirmed
in an independent study with hemodialysis patients,
where the levels of PTH(1-84) were 99% ± 5% from the
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Table 2: Percent change from the baseline plasma sample corresponding to the log transformed data in Figure 3.
Tube type

Storage
at RT

Plasma

0h
24 h
72 h
Unspun plasma 0 h
24 h
72 h
SST
0h
24 h
72 h

LIAISON 1-84 PTH
Mean

95% CI

LIAISON N-TACT PTH Method A intact PTH

Method B intact PTH

Method C intact PTH

Mean

Mean

Mean

95% CI

Mean

100%
100%
102% 95%–108% 96% 91%–101%
96% 88%–104% 95% 88%–103%
107% 104%–110% 108% 103%–112%
101% 94%–107% 105% 99%–112%
101% 94%–109% 102% 92%–112%
107% 101%–114% 111% 103%–120%
99% 91%–107% 101% 92%–110%
82%
73%–89% 82%
72%–91%

100%
93%
95%
103%
101%
95%
110%
89%
72%

95% CI

95% CI

95% CI

100%
100%
80%–106% 98% 93%–103% 125% 104%–145%
84%–106% 97% 92%–102% 133% 104%–162%
91%–115% 106% 102%–110% 109% 97%–121%
88%–114% 100% 96%–105% 116% 103%–129%
84%–105% 99% 93%–105% 122% 95%–149%
94%–127% 104% 99%–108% 92% 77%–107%
75%–103% 99% 92%–107% 82%
66%–98%
59%–84% 86%
79%–93% 78%
65%–91%

Table 3: Analysis of variance of the changes in PTH from baseline plasma samples.
0h

LIAISON 1-84 PTH
Plasma
Plasma unspun
SST
LIAISON N-TACT
Plasma
Plasma unspun
SST
Method B iPTH
Plasma
Plasma unspun
SST
Method A iPTH
Plasma
Plasma unspun
SST
Method C iPTH
Plasma
Plasma unspun
SST

24 h

Effect

SE

Ref
0.010
−0.050

Ref
0.033
0.033

Ref
−0.046
−0.057

t

p-Value

Effect

SE

t

0.29
−1.49

0.065
−0.002
0.005

0.033
0.033
0.033

Ref
0.038
0.038

−1.21
−1.50

0.071
0.044
0.003

Ref
−0.016
−0.033

Ref
0.026
0.026

−0.61
−1.29

Ref
−0.101
−0.089

Ref
0.063
0.061

Ref
0.174
0.219

Ref
0.100
0.100

Effect

SE

t

p-Value

1.95
−0.07
0.14

0.066
−0.017
−0.221

0.033
0.033
0.033

1.99
−0.52
−6.62

<0.05

0.038
0.038
0.038

1.89
1.16
0.09

0.099
−0.003
−0.221

0.038
0.038
0.038

2.62
−0.08
−5.85

<0.001

0.053
0.000
−0.020

0.026
0.026
0.026

2.06
0.01
−0.77

0.034
−0.023
−0.161

0.026
0.027
0.026

1.30
−0.86
−6.07

<0.001

−1.62
−1.44

−0.005
−0.029
−0.082

0.061
0.061
0.061

−0.08
−0.47
−1.33

0.044
−0.177
−0.394

0.061
0.063
0.063

0.72
−2.83
−6.30

<0.01
<0.001

1.74
2.18

0.058
0.121
0.122

0.100
0.100
0.100

0.57
1.21
1.22

−0.169
−0.337
−0.320

0.100
0.100
0.100

−1.68
−3.36
−3.18

<0.01
<0.01

<0.05

T = 0 sample and levels of iPTH were 97% ± 6% (data not
shown).
Multifactor analysis of variance (Table 3) indicates
statistical significance at the 5%, 1% and 0.1% levels.
Although some of the marginally statistically significant differences may be explained as Type I errors from
multiple testing, the larger significant effects observed
across the board for SST samples stored at room temperature for 72 h likely represent true instability. Method A
and Method C show the largest effects, which are likely
a combination of both sample instability and assay
imprecision.

p-Value

72 h

<0.05

<0.001
<0.01

Discussion
In the present study, we found that PTH is stable for up to
72 h in EDTA plasma from hemodialysis, primary hyperparathyroid and apparently healthy subjects across a wide
range of PTH levels. Blood collected in K2 EDTA plastic
lavender top vacutainers stored uncentrifuged at room
temperature for up to 72 h, and then centrifuged, also
demonstrated remarkable PTH stability.
Serum provides a convenient sample type for PTH
testing because its collection obviates the need for collecting a second sample for other tests that are frequently
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ordered concomitantly (calcium, vitamin D metabolites).
However, PTH measurements from unfrozen serum
samples are accurate only if testing is performed within
24 h of collection. Alternatively, serum can be frozen at
collection for subsequent testing on site or at a centralized
laboratory. The advantage of testing from a single matrix
is countered by the extra effort required for transferring
serum to a secondary container, freezing the samples and
thawing/mixing the sample prior to testing. In recognition
of this, laboratories might consider collecting an EDTA
whole blood sample for transfer at the point of collection
for local testing or transportation to a central laboratory
for processing and testing.
Although results generated by three of the five
methods evaluated were quite consistent, two methods
exhibited greater variability as revealed by their much
larger confidence intervals (Figure 3). Methods A and C
have greater cross-reactivity to the PTH(7-84) fragments
that are known to be present at higher levels in hemodialysis patients [13]. Because greater instability in hemodialysis vs. normal or PHPT samples was not observed (data
not shown), the larger confidence intervals likely represent a greater inherent imprecision of these two assays
that is well beyond their stated analytical variability.
Our statistical approach, multifactor analysis of variance, differs from the approach taken by Schleck et al. [8].
Significant observations in the multifactor setup (given by
multiple patient types, multiple sample matrices, multiple
storage durations and multiple assay platforms) are best
identified using a multiway analysis, which better controls Type I error rates, and borrows strength by pooling
information from different cells, which enables more
power [14]. By contrast, doing a collection of paired tests
between these different combinations of factors can lead
to false positives (Type I error) due to the multiplicity of
all the test statistics generated, and at the same time lose
power resulting in a failure to identify factors that actually
matter (Type II errors).
PTH assays are notably quite erratic and provide
dissimilar values depending upon the manufacturer’s
utilization of components with widely variable fragment
cross-reactivity and different standardization regimens
[4]. In this study, average PTH values were 101, 274, 238,
189 and 189 pg/mL for the LIAISON 1-84 PTH, LIAISON
N-TACT and Methods A, B and C, respectively. Although
efforts by the PTH working group to standardize PTH
assays are ongoing, transitioning to the third-generation
PTH assays affords immediate opportunity for true and
standardized measurements, as these PTH(1-84) specific
assays can be aligned with WHO recombinant standards [11] as well as synthetic PTH(1-84). In hemodialysis
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Figure 4: Frequency of fragment content in hemodialysis patients.
Representative PTH fragment was assessed in 1533 hemodialysis
samples by measuring both PTH(1-84) with the LIAISON method,
and iPTH with Method A (high cross-reactivity with inactive
fragments [4]). The fragment content was calculated as (iPTHPTH(1-84))/iPTH and expressed as % of total iPTH.

patients, there is a wide distribution of percent PTHfragment content (Figure 4). These representative data
from 1533 hemodialysis samples illustrate that patients
with similar levels of iPTH and quite different levels of
active PTH(1-84) will respond differently to treatment,
emphasizing the importance of measuring the active
molecule with third-generation assays that are standardized and accurate.
Although the strength of our study resides in the statistical analysis and extended storage times, its major limitation was the inability to normalize to plasma samples
collected and measured immediately without freezing [6].
The design of this study engaged multisite collection and
centralized testing, which did not allow for such a control.
Although Cavalier et al. showed average declines of ~16%
and ~26% in iPTH assays following 1 and 3 months storage
at −80 °C, respectively, in this study the samples were all
processed similarly to mitigate or effectively normalize the
effects of freezing.
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